Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,607.50
(
-0.26%
)
US TECH 100
23,732.40
(
-0.27%
)
Dow Jones
46,072.38
(
-0.33%
)
Brent Oil
103.60
(
-2.80%
)
Bitcoin
70,370.57
(
-1.22%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ciotera

Send PM Follow Ignore
Followers 8
Posts 512
Boards Moderated 0
Alias Born 08/03/2005

ciotera

Re: DewDiligence post# 88663

Friday, 01/08/2010 10:39:16 AM

Friday, January 08, 2010 10:39:16 AM

Post# of 257259
Very little of Reyataz is (or was) prescribed unboosted. Used to be because patients could not tolerate ritonavir and had progressed from first line Sustiva. But that niche (second line NNRTI-resistant patients who can't tolerate ritonavir) is now gone to Isentress.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now